Shares of Sequenom, Inc. (NASDAQ:SQNM) ended Tuesday session in green amid volatile trading. The shares closed up +0.018 points or 1.95% at $0.938 with 425,258.00 shares getting traded. Post opening the session at $0.93, the shares hit an intraday low of $0.92 and an intraday high of $0.95 and the price vacillated in this range throughout the day. The company has a market cap of $111.35 million and the numbers of outstanding shares have been calculated to be 119.22 million shares.
Sequenom, Inc. (SQNM) develops and commercializes molecular diagnostics testing services for the women’s health and oncology markets in the United States and internationally. The company provides molecular based laboratory developed tests (LDTs) comprising MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; and VisibiliT LDT, a NIPT to detect fetal chromosomal abnormalities by determining the relative amount of chromosomal material present in circulating cell-free DNA in a maternal blood sample.
Shares of Idera Pharmaceuticals Inc (NASDAQ:IDRA) ended Tuesday session in green amid volatile trading. The shares closed up +0.02 points or 1.19% at $1.70 with 438,259.00 shares getting traded. Post opening the session at $1.69, the shares hit an intraday low of $1.67 and an intraday high of $1.73 and the price vacillated in this range throughout the day. The company has a market cap of $206.23 million and the numbers of outstanding shares have been calculated to be 121.31 million shares.
Idera Pharmaceuticals Inc (IDRA) a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The companys lead drug candidate is IMO-8400, which is in Phase I/II clinical trials for the treatment of Waldenströms Macroglobulinemia and diffuse large B-cell lymphoma, as well as in Phase II clinical trial for the treatment of dermatomyositis. Its drug candidates also comprise IMO-9200, a drug candidate in Phase I clinical trial for use in selected autoimmune disease indications; and IMO-2055/IMO-2125 that are in Phase I/II clinical trials for applications as immune therapies for the treatment of cancer. In addition, the company is developing drug candidates to turn off the messenger RNA associated with disease causing genes.